Physician profile
Stuart T Smith
NPI 1821196577
$8,244.89
in general payments reported to CMS, 2019-2025
36 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $566 · 2021: $437 · 2022: $1,257 · 2023: $1,519 · 2024: $1,664 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,225.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,069.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,043.05 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $920.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $793.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $717.38 | 2021-2025 | Vraylar, Ubrelvy, Viberzi |
| Astellas Pharma US INC | $463.65 | 2019-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $270.04 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.97 | 2019-2024 | Ofev, Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $167.08 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $165.87 | 2022-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $131.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.57 | 2021-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $100.24 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $100.13 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $81.19 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $76.30 | 2022-2023 | Injectafer |
| Eisai INC. | $71.60 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $64.18 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $61.01 | 2019-2022 | |
| Axsome Therapeutics, INC. | $54.71 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $51.16 | 2019-2023 | Verquvo, Belsomra |
| Radius Health, INC. | $43.82 | 2019-2025 | Tymlos |
| Amarin Pharma, INC. | $36.96 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $35.49 | 2024-2025 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $25.92 | 2023-2024 | Inpefa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.76 | 2022 | |
| Medtronic, INC. | $19.54 | 2024 | Minimed 780g |
| Lundbeck LLC | $19.10 | 2023 | Vyepti |
| Abbott Laboratories | $16.79 | 2022 | |
| Ardelyx, INC. | $15.40 | 2023 | Ibsrela |
| Acadia Pharmaceuticals INC | $14.45 | 2022 | |
| Neurocrine Biosciences, INC. | $13.94 | 2025 | |
| Allergan, INC. | $13.75 | 2019 | |
| Ethicon US, LLC | $13.46 | 2021 | |
| Mylan Specialty L.P. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.